These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 8454328

  • 1. Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever.
    Fries LF, Waag DM, Williams JC.
    Infect Immun; 1993 Apr; 61(4):1251-8. PubMed ID: 8454328
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy and immunogenicity of Q fever chloroform:methanol residue (CMR) and phase I cellular (Q-Vax) vaccines in cynomolgus monkeys challenged by aerosol.
    Waag DM, England MJ, Tammariello RF, Byrne WR, Gibbs P, Banfield CM, Pitt ML.
    Vaccine; 2002 Jun 07; 20(19-20):2623-34. PubMed ID: 12057622
    [Abstract] [Full Text] [Related]

  • 3. Vaccines against coxiellosis and Q fever. Development of a chloroform:methanol residue subunit of phase I Coxiella burnetti for the immunization of animals.
    Williams JC, Peacock MG, Waag DM, Kent G, England MJ, Nelson G, Stephenson EH.
    Ann N Y Acad Sci; 1992 Jun 16; 653():88-111. PubMed ID: 1626897
    [Abstract] [Full Text] [Related]

  • 4. Guinea pig abscess/hypersensitivity model for study of adverse vaccination reactions induced by use of Q fever vaccines.
    Wilhelmsen CL, Waag DM.
    Comp Med; 2000 Aug 16; 50(4):374-8. PubMed ID: 11020154
    [Abstract] [Full Text] [Related]

  • 5. Enhanced protection against Q fever in BALB/c mice elicited by immunization of chloroform-methanol residue of Coxiella burnetii via intratracheal inoculation.
    Feng J, Hu X, Fu M, Dai L, Yu Y, Luo W, Zhao Z, Lu Z, Du Z, Zhou D, Wen B, Jiao J, Xiong X.
    Vaccine; 2019 Sep 24; 37(41):6076-6084. PubMed ID: 31477436
    [Abstract] [Full Text] [Related]

  • 6. Comparative efficacy of a Coxiella burnetii chloroform:methanol residue (CMR) vaccine and a licensed cellular vaccine (Q-Vax) in rodents challenged by aerosol.
    Waag DM, England MJ, Pitt ML.
    Vaccine; 1997 Nov 24; 15(16):1779-83. PubMed ID: 9364683
    [Abstract] [Full Text] [Related]

  • 7. Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular immune responses to Coxiella burnetii.
    Waag DM, England MJ, Bolt CR, Williams JC.
    Clin Vaccine Immunol; 2008 Oct 24; 15(10):1505-12. PubMed ID: 18701647
    [Abstract] [Full Text] [Related]

  • 8. Characterization of a phase I Coxiella burnetii chloroform-methanol residue vaccine that induces active immunity against Q fever in C57BL/10 ScN mice.
    Williams JC, Damrow TA, Waag DM, Amano K.
    Infect Immun; 1986 Mar 24; 51(3):851-8. PubMed ID: 3949384
    [Abstract] [Full Text] [Related]

  • 9. [Experience in vaccinating farm animals for preventing Q fever in humans].
    Lisák V.
    Tr Inst Im Pastera; 1989 Mar 24; 66():143-53, 174. PubMed ID: 2485300
    [Abstract] [Full Text] [Related]

  • 10. Chloroform-Methanol Residue of Coxiella burnetii Markedly Potentiated the Specific Immunoprotection Elicited by a Recombinant Protein Fragment rOmpB-4 Derived from Outer Membrane Protein B of Rickettsia rickettsii in C3H/HeN Mice.
    Gong W, Wang P, Xiong X, Jiao J, Yang X, Wen B.
    PLoS One; 2015 Mar 24; 10(4):e0124664. PubMed ID: 25909586
    [Abstract] [Full Text] [Related]

  • 11. Vaccine prophylaxis of abattoir-associated Q fever: eight years' experience in Australian abattoirs.
    Marmion BP, Ormsbee RA, Kyrkou M, Wright J, Worswick DA, Izzo AA, Esterman A, Feery B, Shapiro RA.
    Epidemiol Infect; 1990 Apr 24; 104(2):275-87. PubMed ID: 2323360
    [Abstract] [Full Text] [Related]

  • 12. Immunization of dogs with Q fever vaccines: comparison of phase I, II and phase I CMR Coxiella burnetii vaccines.
    Williams JC, Peacock MG, Race RE.
    Rev Elev Med Vet Pays Trop; 1993 Apr 24; 46(1-2):87-94. PubMed ID: 8134661
    [Abstract] [Full Text] [Related]

  • 13. Biological and immunological properties of Coxiella burnetii vaccines in C57BL/10ScN endotoxin-nonresponder mice.
    Williams JC, Cantrell JL.
    Infect Immun; 1982 Mar 24; 35(3):1091-102. PubMed ID: 7068212
    [Abstract] [Full Text] [Related]

  • 14. Promiscuous Coxiella burnetii CD4 Epitope Clusters Associated With Human Recall Responses Are Candidates for a Novel T-Cell Targeted Multi-Epitope Q Fever Vaccine.
    Scholzen A, Richard G, Moise L, Baeten LA, Reeves PM, Martin WD, Brauns TA, Boyle CM, Raju Paul S, Bucala R, Bowen RA, Garritsen A, De Groot AS, Sluder AE, Poznansky MC.
    Front Immunol; 2019 Mar 24; 10():207. PubMed ID: 30828331
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Coxiella burnetii and its chloroform-methanol residue (CMR) fraction against Rift Valley fever virus infection in mice.
    Zvilich M, Williams JC, Waag D, Rill WR, Bell P, Kende M.
    Antiviral Res; 1995 May 24; 27(1-2):137-49. PubMed ID: 7486951
    [Abstract] [Full Text] [Related]

  • 16. Subunit Vaccines Using TLR Triagonist Combination Adjuvants Provide Protection Against Coxiella burnetii While Minimizing Reactogenic Responses.
    Fratzke AP, Jan S, Felgner J, Liang L, Nakajima R, Jasinskas A, Manna S, Nihesh FN, Maiti S, Albin TJ, Esser-Kahn AP, Davies DH, Samuel JE, Felgner PL, Gregory AE.
    Front Immunol; 2021 May 24; 12():653092. PubMed ID: 33815413
    [Abstract] [Full Text] [Related]

  • 17. Limited humoral and cellular responses to Q fever vaccination in older adults with risk factors for chronic Q fever.
    Schoffelen T, Herremans T, Sprong T, Nabuurs-Franssen M, Wever PC, Joosten LA, Netea MG, van der Meer JW, Bijlmer HA, van Deuren M.
    J Infect; 2013 Dec 24; 67(6):565-73. PubMed ID: 23973626
    [Abstract] [Full Text] [Related]

  • 18. The effectiveness of Coxiella burnetii vaccines in occupationally exposed populations: a systematic review and meta-analysis.
    O'Neill TJ, Sargeant JM, Poljak Z.
    Zoonoses Public Health; 2014 Mar 24; 61(2):81-96. PubMed ID: 23721172
    [Abstract] [Full Text] [Related]

  • 19. Coxiella burnetii Epitope-Specific T-Cell Responses in Patients with Chronic Q Fever.
    Scholzen A, Richard G, Moise L, Hartman E, Bleeker-Rovers CP, Reeves PM, Raju Paul S, Martin WD, De Groot AS, Poznansky MC, Sluder AE, Garritsen A.
    Infect Immun; 2019 Oct 24; 87(10):. PubMed ID: 31331958
    [Abstract] [Full Text] [Related]

  • 20. Q fever prevention and vaccination.
    Dorko E, Cisláková L.
    Klin Mikrobiol Infekc Lek; 2005 Sep 24; 11(4):128-32. PubMed ID: 16138276
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.